Ministers urged to tackle surge in Asian hornets after rise in sightings
The National Bee Unit says there were 73 credible sightings up to the end of last month – more than double the 28 recorded in the same period last year.
Experts from the unit have also found 28 nests so far this year. One nest can house up to 3,000 of the insects.
Asian hornets, also known as yellow-legged hornets, can badly harm native pollinator insects, including honeybees, threatening food security and ecosystems, ecologists say.
The species was sighted in record numbers in the UK in 2023, and last September UK experts saw evidence for the first time of the queens over-wintering. In May this year, their numbers were described as unprecedented.
The Liberal Democrats have accused the government of not taking the issue seriously enough and are calling for a task force to deal with the problem.
Martin Wrigley, MP for Newton Abbot in Devon, told The Telegraph: 'The previous Conservative government was asleep at the wheel in their response to Asian hornets so the government has got to wake up to the risks and get a grip on this invasive species now – especially ahead of August and September, when new females are born.
'We urgently need a fully fleshed task force dedicated to this invasive insect to reduce delays between reporting nests and their destruction. It's time this government took our biodiversity and the safety of our communities seriously.'
The species, which spread from Asia to Europe in a pottery consignment sent to France in 2004, was first spotted in Britain in 2016, and numbers have been rising since.
The UK Centre for Ecology & Hydrology (UKCEH) has warned that without early detection and a rapid response, the species could gain a foothold in the UK.
Sightings usually peak from September, and people are urged to report any sightings on the Asian Hornet Watch app.
Ian Campbell, of the British Beekeepers Association, said that this year appeared to be a 'surge year' for yellow-legged hornets, in part because of the weather.
'There is significant worry that this year is going to be ahead of 2023, which is the worst year we've had so far,' he said.
He called for authorities to try to eradicate the species before it became fully established.
The invasive species is mostly found in Kent and East Sussex but has also been seen in Surrey, Hampshire and London, and even as far as Co Durham. It's thought they come into the country on vehicles.
Ecologists say that except for parts of Scotland, all of Britain has a suitable climate for yellow-legged hornets.
Asian hornets also have a dark abdomen with a band of yellow, while native hornets' abdomens are predominantly yellow.
A spokesman for the Animal and Plant Health Agency told The Telegraph: 'Our highly skilled staff work 24/7 to tackle the threat of invasive non-native species, which cost the economy nearly £2bn a year.
'The yellow-legged hornet response, as with other outbreaks, is managed through a roster of trained nest destructors and inspectors that is scaled up as required based on reports and seasonal fluctuations.'
They said it was not unexpected to see more reports of sightings as public awareness of the insects increased.
A spokesman for Defra said the government would 'never waver in its duty to protect the UK's biosecurity' and pointed to its establishment of a new £200m biosecurity centre and an additional £10m for new surveillance projects.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
2 hours ago
- Forbes
2 Reasons We Feel Better When Others Are Worse Off — By A Psychologist
Most of us have a natural tendency to compare ourselves to others. This can be explained by social comparison theory, developed by psychologist Leon Festinger, which suggests that we determine our self-worth by comparing ourselves to others. When others experience setbacks, we may experience a range of emotions in response, from empathy to pity to even joy at their misfortune. While feeling happy about someone else's pain may sound strange, it's not as uncommon as you might think. This stems from our tendency for 'downward social comparison.' When we compare downward — i.e., to someone worse off — we often feel better about our own lives. It's a subtle, sometimes unconscious coping mechanism, especially in moments of self-doubt. The emotional experience of pleasure in response to another's misfortune is called Schadenfreude, a German word that combines Schaden, which means 'damage,' and Freude, which means 'joy.' Schadenfreude often occurs in competitive environments. For instance, you may feel happy when an employee who cozies up to your boss performs poorly and gets berated by them. This is because people have an inherent need to feel better about themselves and often acquire a better self-image by comparing themselves to others who may be less fortunate. Consequently, people who feel their self-worth is threatened are more likely to feel Schadenfreude. Here are two key reasons why you may be feeling happy about somebody else's suffering: 1. Schadenfreude May Boost Self-esteem In Competitive Scenarios Why do we feel a sense of guilty pleasure at someone's downfall? In a 2017 study published in the European Journal of Social Psychology, researchers sought to answer this question. They tested whether Schadenfreude met any of these four basic psychological needs: the need for self-esteem, control, belongingness and a meaningful existence. Researchers conducted four experiments, all of which pointed to similar outcomes: Schadenfreude does meet our basic need to reaffirm our social standing through comparisons, especially when we compare ourselves to a rival we're envious of. In the first study, participants were asked to imagine being in a job interview, which was also being attended by their primary university competitor. They were told that only one would get the position. In the competitive scenario, participants felt more schadenfreude and need satisfaction than in non-competitive circumstances. Researchers found that they felt more in charge, experienced higher self-esteem and felt a greater sense of belonging. In another situation, they were asked to recall a real-time scenario when their competitor failed. Once again, researchers found that more schadenfreude led to increased feelings of self-esteem, a greater sense of personal control and a stronger perception of meaning in life. Seeing someone else fail or struggle can shield us from feelings of inadequacy, at least for the time being. When life feels out of control, seeing others in similar or worse positions makes our own experiences feel less like personal failures and more like part of a shared human messiness. This is especially true in more competitive scenarios. We all want to believe we're doing 'okay' in life. If someone else is doing worse than us, it affirms that we're not falling behind. 2. Schadenfreude May Reaffirm Your Belief In A Just World Interestingly, another 2013 study published in the Australian Journal of Psychology found a link between schadenfreude and beliefs in a 'just' world. When people's belief in a just world was threatened, they felt more pleasure when someone else suffered a misfortune. For example, they might laugh more at a story where someone 'gets what they deserve.' This may be because they want to restore their belief that the world is fair. When someone holds such beliefs, they're more likely to think that good things happen to good people, while misfortune finds those who deserve it. If they can't help the victim, they might instead blame the victim or believe the person deserved it. This way, they get to justify the misfortune that befell them. However, this does not always indicate that the victim is deserving of punishment or that they are responsible for the outcome. Does Schadenfreude Make You A Bad Person? Schadenfreude doesn't automatically make you a terrible human being. The practice of downward comparison may feel cruel, but that is not always the intention. These reactions often happen without our conscious awareness, and you may have tried to push these thoughts away, knowing it wasn't right. This sense of awareness and moral grounding is what differentiates you from someone that deliberately wants to watch others fail. However, if you find yourself constantly hoping for someone else's downfall and actively trying to put them in compromising situations, that may be worrisome. Instead of trying to eliminate the instinct entirely, try to notice it but avoid giving it too much power. Otherwise, it may make you complacent and feel less motivated to improve because you think 'at least, I'm not that bad.' If you must compare, try to shift your mindset to lateral or upward comparisons that inspire change. Try to put in effort to grow. Look at people doing 'better' than you and learn from them. If seeing others do better than you makes you feel like you're 'not enough' or that you haven't 'achieved enough,' try comparing yourself to those only one or two steps ahead of you. That way, you can realistically map out your progress. You may also want to mark your progress against your past self. Self-comparison allows you to see how far you've come and where you want to go from here, but like any form of comparison, it's a double-edged sword that can make you spiral about your flaws. The healthiest approach is to learn to accept yourself right where you are, without any sense of comparison, viewing your journey in this life as strictly your own. When you begin to embrace the feeling of being and having 'enough,' you naturally stop engaging in self-destructive behaviors or trying to bring others down. Do you often take pleasure in others' misfortune to make yourself feel better? Take this science-backed test to find out: The Schadenfreude Scale
Yahoo
3 hours ago
- Yahoo
75,000 years old: Europe's oldest Arctic animal community discovered in Norway cave
The bones of a vast community of 46 animals in a 75,000-year-old cave in Norway have provided a stunning and rare snapshot of a vanished Arctic world. Researchers only recently discovered and explored Arne Ovamgrotta, but the ancient cave has held a significant collection of animal bones for 75,000 years. Researchers confirmed the finding of 46 different types of animals, hinting at the existence of a large community banding together to weather the cold. Their remains represent the oldest example of an animal community in the European Arctic during this warmer period of the Ice Age and provide an unprecedented first look at a community struggling, if not failing to survive, climate change. According to a new study published in the Proceedings of the National Academy of Sciences (PNAS), the study authors believe the newly discovered bones will feed conservation efforts today by helping researchers understand 'resilience and extinction risk in the present.' These animals didn't survive the Ice Age According to study author Dr. Sam Walker of Bournemouth University and the University of Oslo, this 'rare snapshot of a vanished Arctic world' included an impressive, if not astonishing, assemblage of bones. Among the animals were polar bears, walruses, bowhead whales, Atlantic puffins, common eiders, rock ptarmigans, and Atlantic cod. Additionally, as per a press release, they found collared lemmings, which no one had ever uncovered in Scandavia previously, a species now extinct in Europe. The massive number communicated to researchers that temperatures had increased significantly enough 75,000 years ago to allow these animals passage to the cave. Reindeer, porpoise, and freshwater fish bones further told researchers that rivers and lakes returned to this area. 'The cave has now revealed a diverse mix of animals in a coastal environment representing both the marine and the terrestrial environment,' according to a press release. A picture of this region on Earth became clearer than ever as remains over 10,000 years old are a rare find. This underexplored period during the Ice Age saw the melting of ice, which was enough to support a struggling community of animals. Warnings for our future DNA testing found that these animals did not survive when temperatures dropped back to bone-chilling and fatal degrees. Harsh sheets of ice returned to the region, preventing any possibility of migrating elsewhere, as per Popsci. 'This highlights how cold-adapted species struggle to adapt to major climatic events. This has a direct link to the challenges they are facing in the Arctic today as the climate warms at a rapid pace,' said Dr Walker. 'The habitats these animals in the region live in today are much more fractured than 75,000 years ago, so it is even harder for animal populations to move and adapt,' Dr. Walker continued. 'It is also important to note that this was a shift to a colder, not a period of warming, that we are facing today,' senior author Professor Boessenkool says. 'And these are cold-adapted species – so if they struggled to cope with colder periods in the past, it will be even harder for these species to adapt to a warming climate,' she concludes in a press release. Read the study in the Proceedings of the National Academy of Sciences. Solve the daily Crossword
Yahoo
7 hours ago
- Yahoo
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry
Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 19.7 billion by 2034. Market expansion is being fueled by a growing focus on biologics and biosimilars, particularly as the pharmaceutical industry shifts toward personalized therapies and precision medicine. The surge in demand for monoclonal antibodies, vaccines, and recombinant proteins has placed strong emphasis on the development of highly stable and productive cell lines. The increase in chronic illnesses-such as autoimmune diseases, cancer, and infectious disorders-has led to the rising adoption of biologics, which depend heavily on well-characterized cell lines. This has also elevated the need for quality-controlled production systems. Contract development and manufacturing organizations (CDMOs) have contributed significantly to market momentum. Small and mid-sized biotech firms are increasingly outsourcing their cell line development to CDMOs to reduce overhead costs and accelerate timelines, benefiting from their technical expertise, scalable platforms, and regulatory compliance with agencies like the FDA. This trend allows companies to focus on core competencies such as research and innovation while leveraging CDMOs for end-to-end services including cell line screening, clone selection, process optimization, and GMP manufacturing. These partnerships also offer access to advanced technologies, streamlined workflows, and proven quality assurance frameworks, enabling faster entry into clinical trials and reducing risks associated with internal capacity limitations. The reagents and media segment generated USD 3.4 billion in 2024. This segment continues to dominate due to its central role in cell growth and maintenance across both R&D and production stages. With a notable increase in the use of mammalian cells for biologics manufacturing, the demand for high-efficiency reagents and cell culture media has surged. A growing preference for protein-free and serum-free media is helping the segment gain traction, offering improved scalability, reduced risk of contamination, and consistency in large-scale production environments. Such media types are essential for regulatory approval and efficiency in biologics manufacturing, which demands stringent process control. In terms of cell type, the mammalian cells segment generated the highest revenue in 2024, accounting for 71.4%. Their dominance is linked to their superior ability to express human-compatible therapeutic proteins with accurate post-translational modifications. Widely used cell lines such as CHO and HEK-293 are favored in biologics production due to their robust protein folding, glycosylation, and scalability. Technological progress in gene editing tools, such as CRISPR-Cas9, combined with automation and high-throughput systems, continues to enhance the speed and stability of mammalian cell line development, further reinforcing their leadership in the market. The United States Cell Line Development Market was valued at USD 2.6 billion in 2024, driven by a combination of advanced biopharma infrastructure, high rates of chronic disease, and strong adoption of cutting-edge biologic therapies. The country's well-established pharmaceutical ecosystem, which includes top-tier biotech firms and extensive R&D investment, plays a pivotal role in expanding the market. Research institutions and innovation hubs across the US are also accelerating technological advancements in gene editing and automated platforms, leading to faster and more efficient development cycles. Government and private sector funding are also propelling innovation, further supporting the country's leadership in the field. Key companies operating in the Global Cell Line Development Market include PromoCell, Novartis, Genscript Biotech, Sartorius, Thermo Fisher Scientific, ProBioGen, Cytiva (Danaher Corporation), ASIMOV, Advanced Instruments, Sigma Aldrich (Merck KGaA), Eurofins Scientific, WuXi AppTec, Aragen Life Sciences, Fyonibio, and Lonza Group. Top-tier players in the cell line development space are heavily investing in technological innovations like automated cell screening platforms, single-use bioreactors, and CRISPR-based genome editing. Many companies are forming strategic alliances with biotech firms and CDMOs to enhance service offerings and expand production capabilities. Acquisitions are also a popular move to integrate novel technologies or gain regional access. Firms are focusing on R&D to develop serum-free and chemically defined media, helping improve regulatory compliance and scalability. Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 145 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $7.5 Billion Forecasted Market Value (USD) by 2034 $19.7 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics CoveredChapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 synopsis2.2 Key market trends2.2.1 Regional2.2.2 Products & services2.2.3 Source2.2.4 Cell line2.2.5 Application2.2.6 End use2.3 CXO perspectives: Strategic imperatives2.3.1 Key decision points for industry executives2.3.2 Critical success factors for market players2.4 Future outlook and strategic recommendationsChapter 3 Industry Insights3.1 Industry ecosystem analysis3.1.1 Supplier landscape3.1.2 Value addition at each stage3.1.3 Factors affecting the value chain3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing vaccine production worldwide3.2.1.2 Increasing prevalence of cancer across the globe3.2.1.3 Technological innovations in cell line development3.2.1.4 Growing biotechnology industry3.2.2 Industry pitfalls and challenges3.2.2.1 Complex regulatory landscape3.2.2.2 Challenges related to stem cell research3.2.3 Market opportunities3.2.3.1 Emerging applications in personalized medicine and regenerative therapies3.2.3.2 Adoption of artificial intelligence in cell line optimization3.3 Growth potential analysis3.4 Regulatory landscape3.4.1 North America3.4.2 Europe3.4.3 Asia Pacific3.4.4 Latin America3.4.5 Middle East and Africa3.5 Future market trends3.6 Emerging therapeutic applications of CHO cell lines3.7 Technology landscape3.7.1 Current technological trends3.7.2 Emerging technologies3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Key developments4.6.1 Merger and acquisition4.6.2 Partnership and collaboration4.6.3 New product launches4.6.4 Expansion plansChapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2034 ($ Mn)5.1 Key trends5.2 Reagents and media5.3 Equipment5.3.1 Incubator5.3.2 Centrifuges5.3.3 Bioreactors5.3.4 Storage equipment5.3.5 Microscopes5.3.6 Electroporators5.3.7 Fluorescence-activated cell sorting5.3.8 Other equipment5.4 Accessories and consumables5.5 ServicesChapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)6.1 Key trends6.2 Mammalian6.2.1 Chinese Hamster Ovary (CHO)6.2.2 Human Embryonic Kidney (HEK)6.2.3 Baby Hamster Kidney (BHK)6.2.4 Murine myeloma6.2.5 Other mammalian sources6.3 Non-mammalian6.3.1 Insects6.3.2 AmphibiansChapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2034 ($ Mn)7.1 Key trends7.2 Recombinant7.3 Hybridomas7.4 Continuous cell lines7.5 Primary cell linesChapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)8.1 Key trends8.2 Bioproduction8.3 Drug discovery8.4 Toxicity testing8.5 Tissue engineering8.6 ResearchChapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)9.1 Key trends9.2 Pharmaceutical and biotechnology companies9.3 Academic and research institutes9.4 Contract research organizations (CROs)Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)10.1 Key trends10.2 North America10.2.1 U.S.10.2.2 Canada10.3 Europe10.3.1 Germany10.3.2 UK10.3.3 France10.3.4 Italy10.3.5 Spain10.3.6 Netherlands10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 India10.4.4 Australia10.4.5 South Korea10.5 Latin America10.5.1 Brazil10.5.2 Mexico10.6 Middle East and Africa10.6.1 South Africa10.6.2 Saudi Arabia10.6.3 UAEChapter 11 Company Profiles11.1 Advanced Instruments11.2 Aragen Life Sciences11.3 ASIMOV11.4 Cytiva (Danaher Corporation)11.5 Eurofins Scientific11.6 Fyonibio11.7 Genscript Biotech11.8 Lonza Group11.9 Novartis11.10 ProBioGen11.11 PromoCell11.12 Sartorius11.13 Sigma Aldrich (Merck KGaA)11.14 Thermo Fisher Scientific11.15 WuXi AppTecFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Line Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data